INTELLIGENT BIO SOLUTIONS INC. INBS
refer to Intelligent Bio Solutions Inc. together with its wholly owned subsidiaries.
Bio Solutions Inc. and its wholly owned Delaware subsidiary, GBS Operations Inc., were each formed on December
5, 2016, under the laws of the state of Delaware. The Company's Australian subsidiary, Intelligent Bio Solutions (APAC) Pty Ltd, was formed on August 4, 2016, under the laws of New South Wales,
Australia. On October 4, 2022, INBS acquired Intelligent Fingerprinting Limited ("IFP"), a company registered in England
Last close
1.59
2026-10-23
Market cap
$4.8M
2026-06-30 share count
52-week range
1.35 - 24.90
Valuation FY2026 figures against the last close
P/S1.1x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-8.44
Annual financial statements
Income statement
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.2M | $3.1M | $3.1M | $1.3M | $437.1K | $2.0M | $188.7K | — |
| Cost of revenue | $2.2M | $1.8M | $1.7M | $930.2K | — | — | — | — |
| Gross profit | $2.0M | $1.2M | $1.4M | $326.7K | — | — | — | — |
| SG&A | $10.5M | $8.9M | $9.3M | $8.0M | $4.9M | $3.4M | $2.2M | — |
| Total operating expenses | $15.3M | $12.7M | $12.1M | $13.7M | $8.8M | $7.6M | $3.0M | — |
| Operating income | -$12.6M | -$10.7M | -$10.3M | -$12.6M | -$8.3M | -$5.6M | -$2.9M | — |
| Interest expense | $10.7K | $26.3K | $167.1K | — | — | — | — | — |
| Pre-tax income | — | — | — | — | — | -$7.1M | -$3.2M | — |
| Net income | -$12.4M | -$10.6M | -$10.2M | -$10.6M | -$8.3M | -$7.0M | -$3.2M | — |
| EPS, basic | -8.44 | -20.04 | -6.38 | -127.00 | -11.33 | -0.68 | — | — |
| EPS, diluted | -8.44 | -20.04 | -6.38 | -127.00 | -11.33 | -0.68 | -0.37 | — |
| Shares, diluted (wtd. avg.) | 1.5M | 527,364 | 1.6M | 83,717 | 733,263 | 10.4M | — | — |
Balance sheet
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.0M | $1.0M | $6.3M | $1.5M | $8.2M | $12.6M | $427.3K | — |
| Receivables | $848.5K | $594.6K | $429.7K | $293.9K | — | — | — | — |
| Inventory | $418.6K | $635.2K | $777.5K | $979.9K | — | — | — | — |
| Total current assets | $7.1M | $4.1M | $8.5M | $3.9M | $10.9M | $18.2M | $2.3M | — |
| Property, plant and equipment | $294.4K | $251.3K | $565.9K | $690.2K | $391.4K | — | — | — |
| Goodwill | — | — | — | — | $3.8M | — | — | — |
| Other intangibles | $2.8M | $3.8M | $4.4M | $5.3M | — | — | — | — |
| Total assets | $11.9M | $8.2M | $13.8M | $10.4M | $12.4M | $21.9M | $2.5M | — |
| Accounts payable | $712.4K | $897.3K | $1.7M | $2.6M | $1.6M | $1.5M | $787.5K | — |
| Total current liabilities | $4.9M | $5.4M | $5.5M | $5.9M | $4.7M | $3.7M | $7.7M | — |
| Long-term debt | — | — | — | $1.6M | — | — | — | — |
| Total liabilities | $6.7M | $5.4M | $5.6M | $6.7M | $5.8M | $6.9M | $7.7M | — |
| Retained earnings | -$75.0M | -$62.5M | -$52.0M | -$41.8M | -$31.2M | -$22.9M | -$15.8M | — |
| Total equity | $5.5M | $3.0M | $8.2M | $3.7M | $6.5M | $15.0M | -$5.2M | -$4.0M |
Cash flow
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.9M | -$9.7M | -$9.6M | -$7.4M | -$3.4M | -$11.3M | -$498.6K | — |
| Depreciation and amortisation | $68.3K | $27.1K | $974.4K | $814.5K | $0 | — | — | — |
| Stock-based compensation | $195.2K | $238.0K | $230.5K | $260.0K | — | — | — | — |
| Capital expenditure | $125.7K | $231.8K | $221.4K | — | — | — | — | — |
| Investing cash flow | -$85.6K | -$231.8K | -$221.4K | -$694.1K | -$880.2K | — | -$14.0K | — |
| Financing cash flow | $15.0M | $4.6M | $14.6M | $1.4M | — | $23.4M | $733.9K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-039136.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $188.7K | $2.0M | $437.1K | $1.3M | $3.1M | $3.1M | $4.2M |
| Gross profit | — | — | — | — | $326.7K | $1.4M | $1.2M | $2.0M |
| Net income | — | -$3.2M | -$7.0M | -$8.3M | -$10.6M | -$10.2M | -$10.6M | -$12.4M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |